BNP/CALL/ASTRAZENECA/10000/0.1/19.12.25 Stock

DE000PC5CA34

Real-time Boerse Frankfurt Warrants 11:20:57 2024-07-05 EDT
3.49 ^EUR	-2.51%

Current month	-7.73%
1 month	-8.21%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart ASTRAZENECA PLC

Chart BNP/CALL/ASTRAZENECA/10000/0.1/19.12.25

Latest news about ASTRAZENECA PLC

AstraZeneca's Tagrisso Approved by EU as First-Line Treatment for Non-Small Cell Lung Cancer	09:10am	MT
AstraZeneca: cancer treatment approved by the EU	07:39am	CF
AstraZeneca drug Tagrisso gets EU approval for cancer form	03:38am	AN
EU Approves AstraZeneca's Tagrisso Combo as Non-small Cell Lung Cancer Treatment	02:38am	MT

More news

Quotes 5-day view

Date	Price	Change
24-07-05	3.49	-2.51%
24-07-04	3.58	+3.17%
24-07-03	3.47	-2.80%
24-07-02	3.57	-6.30%
24-07-01	3.81	-1.80%

Real-time Boerse Frankfurt Warrants

Last update July 05, 2024 at 11:20 am

More quotes

Static data

Product type	Warrants
Buy / Sell	CALL
Underlying	ASTRAZENECA PLC
Issuer	BNP Paribas
WKN	PC5CA3
ISIN	DE000PC5CA34
Date issued	2024-02-20
Strike	10,000 p
Maturity	2025-12-19 (532 Days)
Parity	10 : 1
Emission price	1.52 €
Emission volume	N/A
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Highest since issue	4.18 €
Lowest since issue	1.76 €
Delta	0.85x
Omega	3.478
Premium	7.84x
Gearing	4.08x
Moneyness	1.200
Difference Strike	-2,026 p
Difference Strike %	-20.26%
Spread	0.01 €
Spread %	0.29%
Theoretical value	3.495
Implied Volatility	22.70 %
Total Loss Probability	21.71 %
Intrinsic value	2.389
Present value	1.106
Break even	12,955.10 €
Theta	-0.01x
Vega	0.04x
Rho	0.13x

Company Profile

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).

Sector

More about the company